{"url_path":"/sec/rkto/10-q/2026/item-4","section_key":"item-4","section_title":"Item 4 CONTROLS AND PROCEDURES","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1711786/0001213900-26-057726-index.html","accession_number":"0001213900-26-057726","cik":"0001711786","ticker":"RKTO","issuer_name":"Rocket One Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1711786/0001213900-26-057726-index.html","primary_entity_key":"0001711786","primary_entity_name":"Hoth Therapeutics, Inc."},"word_count":191,"has_tables":true,"body_markdown":"ITEM 4. CONTROLS AND PROCEDURES\n\n \n\nOur management, with the participation of our\n principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures\n(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2026, the end of the\nperiod covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well\ndesigned and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment\nin evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer\nand Chief Financial Officer have concluded that, as of the end of the period covered by this report, as of such date, our disclosure controls\nand procedures were effective.\n\n \n\nChanges in Internal Control Over Financial\nReporting\n\n \n\nThere have been no changes in our internal control\nover financial reporting that occurred during our last fiscal quarter ended March 31, 2026 that have materially affected, or are reasonably\nlikely to materially affect, our internal control over financial reporting.\n\n \n\n27\n\n \n\n \n\nPART II – OTHER INFORMATION"}